![]() Predictors of cognitive impairment in an early stage Parkinson's disease cohort. , 7 7 Hu MT, Szewczyk-Królikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, et al. Use of the Montreal Cognitive Assessment and Alzheimer's Disease-8 as Cognitive Screening Measures in Parkinson Disease. 3 3 Brown DS, Bernstein IH, McClintock SM, Munro CC, Dewey RBJ, Husain M, et al. The Movement Disorder Society Task Force recommends the Montreal Cognitive Assessment (MOCA) as a minimal standard or cognitive screening instrument in PD clinical trials. Measuring Mild Cognitive Impairment in Patients With Parkinson's Disease. 6 6 Marras C, Armstrong MJ, Meaney CA, Fox S, Rothberg B, Tang-Wai DF, et al. Cognitive training in Parkinson disease: a systematic review and meta-analysis. 2014 29(10):1258-64.ĥ Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. 2016 31(3):264-72.Ĥ Burdick DJ, Cholerton B, Watson GS, Siderowf A, Trojanowski JQ, Weintraub D, et al. 2010 75(12):1062-9.ģ Brown DS, Bernstein IH, McClintock SM, Munro CC, Dewey RBJ, Husain M, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. 2005 20(10): 1255-63.Ģ Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. A systematic review of prevalence studies of dementia in Parkinson's disease. Cognitive impairment is associated with decreased quality of life, increased functional disability, caregiver distress and institutionalization. Para distinguir DP-P de CCL, o ponto de corte foi de 17.5 (IC 95% 0.758-0.951), sensibilidade de 81.6% e especificidade de 76%.ĭoença de Parkinson MOCA-BR demência na doença de Parkinson (DP-D) comprometimento cognitivo leve (DP-CCL) avaliação cognitivaĪmong non-motor manifestations, cognitive impairment is recognized as a common component of Parkinson disease (PD) and includes dementia (PD-D) and mild cognitive impairment (PD-MCI). O valor de corte no MOCA-BR para distinguir entre DP-N de DP-D foi 22.5 (IC 95% 0.748-0.943), sensibilidade de 85.5% e especificidade de 71.1%. Na avaliação cognitiva, foram encontrados 30.3% de DP-N, 41.6% de DP-CCL e 28.1% DP-D. ![]() Os pacientes foram selecionados depois de avaliações consecutivas por um neurologista, após avaliação cognitiva extensa, e foram classificados como cognição normal (DP-N), DP-CCL e DP-D e então o MOCA-BR foi aplicado, sendo selecionados 89 pacientes. ![]() Trata-se de um estudo transversal, analítico, com uma abordagem quantitativa. O presente estudo tem o objetivo de definir os valores de corte na escala de MOCA-BR para diagnosticar o Comprometimento Cognitivo Leve (DP-CCL) e Demência (DP-D) em pacientes com DP. Entretanto, poucos estudos foram aplicados à versão em português (MOCA-BR). Parkinson’s disease MOCA-BR dementia in Parkinson’s disease (PD-D) mild cognitive impairment (PD-MCI) cognitive assessmentĪ Movement Disorder Society publicou algumas recomendações para o diagnóstico de demência na doença de Parkinson (DP), propondo o Montreal Cognitive Assessment (MOCA) como ferramenta de triagem cognitiva nesses pacientes. The cut-off for distinguishing PD-D from MCI was 17.50 (95% CI 0.758-0.951) for sensitivity of 81.6% and specificity of 76%. The cut-off score on the MOCA-Br to distinguish PD-N from PD-D was 22.50 (95% CI 0.748-0.943) for sensitivity of 85.5% and specificity of 71.1%. On the cognitive assessment, 30.3% were PD-N, 41.6% PD-MCI and 28.1% PD-D. The MOCA-BR was then applied and 89 patients selected. Patients were selected after a consecutive assessment by a neurologist, after an extensive cognitive evaluation, and were classified as having normal cognition (PD-N), PD-MCI or PD-D. ![]() This was a cross-sectional, analytic field study based on a quantitative approach. The aim of the present study was to define the cut-off points of the MOCA-BR scale for diagnosing Mild Cognitive Impairment (PD-MCI) and Dementia (PD-D) in patients with PD. However, few studies have been conducted assessing the Portuguese version of this test in Brazil (MOCA-BR). The Movement Disorder Society has published some recommendations for dementia diagnosis in Parkinson disease (PD), proposing the Montreal Cognitive Assessment (MOCA) as a cognitive screening tool in these patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |